Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Analyst Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRDN Stock 12 Month Forecast
Average Price Target
$38.80
▲(170.76%Upside)
| Highest Price Target$61.00 | Average Price Target$38.80 | Lowest Price Target$19.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$14.5
Hold
1.19%
Upside
Reiterated
06/25/25
Viridian Therapeutics' overall stock score reflects significant financial challenges, mitigated by positive corporate events and neutral technical indicators. The strong phase 3 trial results and strategic board appointment provide a positive outlook, but persistent financial difficulties and negative valuation metrics weigh heavily on the overall score.
Stifel Nicolaus
$12.82→$41
Buy
186.11%
Upside
Reiterated
05/26/25
B.Riley Financial
$19
Hold
32.59%
Upside
Reiterated
05/21/25
Leerink Partners
―
Buy
―
Reiterated
05/20/25
LifeSci Capital
$46
Buy
221.00%
Upside
Reiterated
05/20/25
H.C. Wainwright
$34
Buy
137.26%
Upside
Reiterated
05/20/25
BTIG
$61
Buy
325.68%
Upside
Reiterated
05/20/25
Wedbush
$41
Buy
186.11%
Upside
Reiterated
05/20/25
Needham
$36
Buy
151.22%
Upside
Reiterated
05/20/25
TD Cowen
―
Buy
―
Reiterated
05/20/25
Citizens JMP
$42→$38
Buy
165.18%
Upside
Reiterated
05/07/25
RBC Capital
$46→$45
Buy
214.03%
Upside
Reiterated
05/06/25
Wells Fargo
$27
Hold
88.42%
Upside
Reiterated
05/06/25
Oppenheimer
$28
Buy
95.39%
Upside
Reiterated
12/17/24
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$41
Buy
186.11%
Upside
Assigned
12/17/24
We wish mgmt. showed the proptosis/diplopia data specifically in the baseline CAS0/1 subgroup to definitively address this point, but did note on the call that benefit on both measures was independent of CAS response – which is a clear positive. Even if some investors remain skeptical and want to see this full data, the point remains that VRDN clearly has this as an (on label) marketing advantage over Tepezza (in addition to infusion time, # cycles). Point #2) safety, mainly hearing events, is solid and largely in line with THRIVE We continue to focus most on hearing impairments, since that has the most readthrough to long T1/2 subQ 003. Pbo came
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$14.5
Hold
1.19%
Upside
Reiterated
06/25/25
Viridian Therapeutics' overall stock score reflects significant financial challenges, mitigated by positive corporate events and neutral technical indicators. The strong phase 3 trial results and strategic board appointment provide a positive outlook, but persistent financial difficulties and negative valuation metrics weigh heavily on the overall score.
Stifel Nicolaus
$12.82→$41
Buy
186.11%
Upside
Reiterated
05/26/25
B.Riley Financial
$19
Hold
32.59%
Upside
Reiterated
05/21/25
Leerink Partners
―
Buy
―
Reiterated
05/20/25
LifeSci Capital
$46
Buy
221.00%
Upside
Reiterated
05/20/25
H.C. Wainwright
$34
Buy
137.26%
Upside
Reiterated
05/20/25
BTIG
$61
Buy
325.68%
Upside
Reiterated
05/20/25
Wedbush
$41
Buy
186.11%
Upside
Reiterated
05/20/25
Needham
$36
Buy
151.22%
Upside
Reiterated
05/20/25
TD Cowen
―
Buy
―
Reiterated
05/20/25
Citizens JMP
$42→$38
Buy
165.18%
Upside
Reiterated
05/07/25
RBC Capital
$46→$45
Buy
214.03%
Upside
Reiterated
05/06/25
Wells Fargo
$27
Hold
88.42%
Upside
Reiterated
05/06/25
Oppenheimer
$28
Buy
95.39%
Upside
Reiterated
12/17/24
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$41
Buy
186.11%
Upside
Assigned
12/17/24
We wish mgmt. showed the proptosis/diplopia data specifically in the baseline CAS0/1 subgroup to definitively address this point, but did note on the call that benefit on both measures was independent of CAS response – which is a clear positive. Even if some investors remain skeptical and want to see this full data, the point remains that VRDN clearly has this as an (on label) marketing advantage over Tepezza (in addition to infusion time, # cycles). Point #2) safety, mainly hearing events, is solid and largely in line with THRIVE We continue to focus most on hearing impairments, since that has the most readthrough to long T1/2 subQ 003. Pbo came
Best Analysts Covering Viridian Therapeutics
1 Month
xxx
Success Rate
18/40 ratings generated profit
Average Return
-0.77%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.00% of your transactions generating a profit, with an average return of -0.77% per trade.
3 Months
xxx
Success Rate
12/23 ratings generated profit
Average Return
+1.40%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +1.40% per trade.
1 Year
Success Rate
17/40 ratings generated profit
Average Return
-3.94%
reiterated a buy rating last month
Copying Laura Chico's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of -3.94% per trade.
2 Years
xxx
Success Rate
9/25 ratings generated profit
Average Return
+10.43%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 36.00% of your transactions generating a profit, with an average return of +10.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRDN Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
30
25
14
11
16
Buy
5
6
5
3
4
Hold
1
2
1
1
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
33
20
15
23
Each month's total comprises the sum of three months' worth of ratings.
VRDN Financial Forecast
VRDN Stock Forecast FAQ
What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 38.80.
What is VRDN’s upside potential, based on the analysts’ average price target?
Viridian Therapeutics has 170.76% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRDN a Buy, Sell or Hold?
Viridian Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
What is Viridian Therapeutics’s price target?
The average price target for Viridian Therapeutics is 38.80. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $19.00. The average price target represents 170.76% Increase from the current price of $14.33.
The highest analyst price target is $61.00 ,the lowest forecast is $19.00. The average price target represents 170.76% Increase from the current price of $14.33.
What do analysts say about Viridian Therapeutics?
Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of VRDN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.